217 related articles for article (PubMed ID: 16983183)
1. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
3. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
4. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
5. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
6. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR
Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
[TBL] [Abstract][Full Text] [Related]
7. Decreased hearing after combined modality therapy for head and neck cancer.
Pearson SE; Meyer AC; Adams GL; Ondrey FG
Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
[TBL] [Abstract][Full Text] [Related]
8. [Hearing loss caused by high dose carboplatin therapy].
Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
10. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients.
Scobioala S; Parfitt R; Matulat P; Kittel C; Ebrahimi F; Wolters H; Am Zehnhoff-Dinnesen A; Eich HT
Strahlenther Onkol; 2017 Nov; 193(11):910-920. PubMed ID: 28887665
[TBL] [Abstract][Full Text] [Related]
11. Comparison of radiation and chemoradiation-induced sensorineural hearing loss in head and neck cancer patients.
Mahdavi SR; Rezaeyan A; Nikoofar A; Bakhshandeh M; Farahani S; Cheraghi S
J Cancer Res Ther; 2020; 16(3):539-545. PubMed ID: 32719264
[TBL] [Abstract][Full Text] [Related]
12. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
13. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.
Schuette A; Lander DP; Kallogjeri D; Collopy C; Goddu S; Wildes TM; Daly M; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2020 Feb; 146(2):106-112. PubMed ID: 31750863
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M
J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose cisplatin-based chemo-irradiation in assessing hearing loss for locally advanced head and neck cancer.
Liao XB; Yan SX
Radiother Oncol; 2009 Feb; 90(2):282, author reply 282-3. PubMed ID: 19042049
[No Abstract] [Full Text] [Related]
16. A new grading system for ototoxicity in adults.
Theunissen EA; Dreschler WA; Latenstein MN; Rasch CR; van der Baan S; de Boer JP; Balm AJ; Zuur CL
Ann Otol Rhinol Laryngol; 2014 Oct; 123(10):711-8. PubMed ID: 24820112
[TBL] [Abstract][Full Text] [Related]
17. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study.
Low WK; Toh ST; Wee J; Fook-Chong SM; Wang DY
J Clin Oncol; 2006 Apr; 24(12):1904-9. PubMed ID: 16622266
[TBL] [Abstract][Full Text] [Related]
18. Long-term hearing loss after chemoradiation in patients with head and neck cancer.
Theunissen EA; Zuur CL; Bosma SC; Lopez-Yurda M; Hauptmann M; van der Baan S; de Boer JP; van der Molen L; Rasch CR; Dreschler WA; Balm AJ
Laryngoscope; 2014 Dec; 124(12):2720-5. PubMed ID: 24964759
[TBL] [Abstract][Full Text] [Related]
19. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Das N; Kaushal D; Patro SK; Pareek P; Dixit A; Soni K; Prakasan Nair N; Choudhury B; Goyal A
Acta Otolaryngol; 2021 Sep; 141(9):885-893. PubMed ID: 34486907
[TBL] [Abstract][Full Text] [Related]
20. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
